Last reviewed · How we verify
Leptin Human
At a glance
| Generic name | Leptin Human |
|---|---|
| Also known as | Obesecure |
| Sponsor | Hafiz Muhammad Asif |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Physical Exercise and Biomolecular Analysis to Reduce Uremic Toxins in Chronic Kidney Disease: An Exploratory Study (NA)
- Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy (PHASE3)
- Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy (PHASE3)
- Gestational Diabetes and Human Milk Composition Study
- The Physiology of Human Brown Adipose Tissue
- Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL (PHASE3)
- Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy (PHASE4)
- Plant-Based Meat Analogues and Human Health (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leptin Human CI brief — competitive landscape report
- Leptin Human updates RSS · CI watch RSS
- Hafiz Muhammad Asif portfolio CI